Page 2,143«..1020..2,1422,1432,1442,145..2,1502,160..»

Scarless wound healing — applying lessons learned from fetal stem cells

Posted: April 11, 2014 at 8:52 am

PUBLIC RELEASE DATE:

10-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 10, 2014In early fetal development, skin wounds undergo regeneration and healing without scar formation. This mechanism of wound healing later disappears, but by studying the fetal stem cells capable of this scarless wound healing, researchers may be able to apply these mechanisms to develop cell-based approaches able to minimize scarring in adult wounds, as described in a Critical Review article published in Advances in Wound Care, a monthly publication from Mary Ann Liebert, Inc., publishers and an Official Journal of the Wound Healing Society. The article is available free on the Advances in Wound Care website.

Michael Longaker, Peter Lorenz, and co-authors from Stanford University School of Medicine and John A. Burns School of Medicine, University of Hawaii, Honolulu, describe a new stem cell that has been identified in fetal skin and blood that may have a role in scarless wound healing. In the article "The Role of Stem Cells During Scarless Skin Wound Healing", the authors propose future directions for research to characterize the differences in wound healing mechanisms between fetal and adult skin-specific stem cells.

"This work comes from the pioneers in the field and delineates the opportunities towards scarless healing in adults," says Editor-in-Chief Chandan K. Sen, PhD, Professor of Surgery and Director of the Comprehensive Wound Center and the Center for Regenerative Medicine and Cell-Based Therapies at The Ohio State University Wexner Medical Center, Columbus, OH.

###

About the Journal

Advances in Wound Care is a monthly journal published online and in print that reports the latest scientific discoveries, translational research, and clinical developments in acute and chronic wound care. Each issue provides a digest of the latest research findings, innovative wound care strategies, industry product pipeline, and developments in biomaterials and skin and tissue regeneration to optimize patient outcomes. The broad scope of applications covered includes limb salvage, chronic ulcers, burns, trauma, blast injuries, surgical repair, skin bioengineering, dressings, anti-scar strategies, diabetic ulcers, ostomy, bedsores, biofilms, and military wound care. Complete tables of content and a sample issue may be viewed on the Advances in Wound Care website.

About the Publisher

More here:
Scarless wound healing -- applying lessons learned from fetal stem cells

Posted in Genetic Engineering | Comments Off on Scarless wound healing — applying lessons learned from fetal stem cells

Lung Institute's Innovative Stem Cell Procedure is Giving End Stage Lung Disease Patients a New Option

Posted: April 11, 2014 at 8:47 am

Tampa, Florida (PRWEB) April 10, 2014

One year ago, Gary Oberschlake was diagnosed with idiopathic pulmonary fibrosis (IPF), a deadly lung disease with no known cause characterized by the permanent scarring of lung tissue. Gary wasnt alone approximately 48,000 others received the same diagnosis last year. Claiming the lives of nearly 40,000 individuals annually, IPF is as deadly as breast cancer.

Doctors told Gary, a family man with a wife, four children, and four grandchildren, his only treatment option was a double lung transplant. Knowing the inherent risks associated with this procedure, including his bodys rejection of the new lungs, Gary refused to accept it as his only chance for survival.

After spending considerable time researching possible alternative options, Gary became fascinated by recent developments in stem cell medicine, and its potential for treating sufferers of chronic lung disease like IPF. His excitement regarding this option was met with doubt expressed by his pulmonologist, who didnt see the clinical viability of stem cells for lung conditions at the time. Despite his doctors reluctance, Gary decided to give stem cell therapy a chance.

According to his wife Debra, when he found Lung Institute in Tampa, FL, it was like it was meant to be. And, feeling as though it was a sign he couldnt ignore, Gary made the decision to pursue autologous stem cell treatment at Lung Institute in Tampa.

Today, nine months after receiving his first treatment at Lung Institute, Gary has seen results that have far exceeded his expectations, leaving his pulmonologist and cardiologist in disbelief. In fact, all the doctors he saw after his treatments have been shocked by his positive progression, which has completely changed their perspective on his prognosis and the viability of stem cells for lung disease in general.

Their astonishment at the treatments overwhelming success is not unusual many doctors like them are skeptical of the clinical application of stem cells for lung disease, simply because advancements in the field have been so recent. But skeptics need only witness the success of these treatments, as Garys doctors did, to have their position turned upside down.

Gary says prior to his stem cell treatment, his cardiologist said the next time hed see me would be in a hospital bed. Quite to the contrary, Gary is now able to enjoy many aspects of life that were previously limited by his condition. In his words, Ive been able to do things with [my grandchildren]. Before I was only able to sit down and watch them.

As a result of his refusal to accept his original prognosis, Gary and his wife are now looking into the future and planning ahead. Lung Institute continues to produce positive results, much like those experienced by Gary, and in doing so, is changing the lives of many suffering from chronic and debilitating pulmonary conditions.

About Lung Institute At Lung Institute (LI), we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook or call us today at 1-855-469-5864.

Here is the original post:
Lung Institute's Innovative Stem Cell Procedure is Giving End Stage Lung Disease Patients a New Option

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Lung Institute's Innovative Stem Cell Procedure is Giving End Stage Lung Disease Patients a New Option

Global Stem Cells Group and Revita Life Sciences Announce Joint Venture to Establish a Stem Cell Training Course in …

Posted: April 11, 2014 at 8:47 am

Miami (PRWEB) April 11, 2014

GlobalStemCellsGroup.com and Revita Life Sciences have announced plans to present the adipose and bone marrow stem cells course hosted by Himanshu Bansal, M.D., May 22-23 in Delhi.

Revita Life Sciences is a biotech company based in Dehli that specializes in stem cell research, training and clinical applications protocol development in regenerative medicine. Stem Cell specialists from both Global Stem Cells Group and Revita will participate in the two-day training program designed to help medical professionals bring stem cell therapies to the physicians office.

The adipose-derived harvesting, isolation and re-integration training course for the advancement of stem cell procedures is a two-day, hands-on intensive training course developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective in office regenerative medicine techniques.

For more information, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cell Group: Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Revita Life Science:

Revita Life Sciences is a biotechnology company that provides complete support to patients from their first inquiry through stem cell therapy performed by a Revita Life Science specialized physician.

Revitas primary objective is the development of stem cell therapies that target areas of significant unmet or poorly met medical need. Years of research and experience have resulted in substantial improvements in the health and condition of patients suffering from a variety of illnesses through stem cell therapy, even where other treatments have failed.

Read the original:
Global Stem Cells Group and Revita Life Sciences Announce Joint Venture to Establish a Stem Cell Training Course in ...

Posted in Cell Therapy | Comments Off on Global Stem Cells Group and Revita Life Sciences Announce Joint Venture to Establish a Stem Cell Training Course in …

Arroyo's stem cell doctor charged with illegal practice

Posted: April 10, 2014 at 9:47 am

The NBI says Park 'misrepresented herself as a licensed physician in several occasions'

CHARGED. The NBI files charges against an alternative medicine doctor based in Tagaytay. File photo by Buena Bernal/Rappler

MANILA, Philippines The National Bureau of Investigation (NBI) on Thursday, April 10, filed before the Tagaytay City Prosecutor's Office a case against former president Gloria Macapagal-Arroyo's stem cell physician for illegal practice of medicine.

Antonia Carandang-Park, an alternative medicine doctor based in Tagaytay City, was charged for having violated Republic Act 2382 or The Medical Act of 1959. Park is the owner and operator of the Green & Young Health & Wellness Center.

The bureau's investigation found that Park "misrepresented herself as a licensed physician [on] several occasions."

Watch this report below,

The NBI Anti-Organized and Transnational Crime Division (AOTCD) was acting on a complaint filed before the bureau by physician Eunice Salazar-Abad, who worked as an aesthetic physician with Park.

According to the NBI, Abad noticed some "irregularities" and the "unorthodox method" of treatment by Park. The NBI also found that Park, whose treatment of Arroyo gained her popularity, did not make an effort to correct news reports that referred to her as a medical doctor.

ILLEGAL PRACTICE. Dr Antonia Park in this Nov 17, 2012 photo taken by Kate Tan. Photo from Bernard Tan.

In her diagnosis of Arroyo, Park supposedly signed an official statement dated July 25, 2012 as "Dra. Antonia Park, M.D.," where she considered stem cell therapy for Arroyo, who's now under hospital arrest for plunder charges at the Veterans Memorial Medical Center in Quezon City. Mrs Arroyo is suffering from a debilitating neck and back pain.

Originally posted here:
Arroyo's stem cell doctor charged with illegal practice

Posted in Stem Cell Therapy | Comments Off on Arroyo's stem cell doctor charged with illegal practice

World-first regeneration of a living organ

Posted: April 10, 2014 at 5:53 am

It may not be to quite the same level achieved by Victor Frankenstein, but work by a team from the University of Edinburgh is likely to have significant real-world implications in the field of regenerative medicine. For the first time, the team has successfully regenerated a living organ in mice, not by using a jolt of electricity, but by manipulating DNA.

The organ in question was the thymus, which is located next to the heart and is an integral part of the immune system. In humans, it achieves most of its growth in early life, continuing to then grow slowly until puberty when it slowly begins to shrink for the remainder of a person's life. It's deterioration with age leaves older people with greater susceptibility to infections, such as flu.

In a study led by researchers from the Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh, levels of a protein called FOXN1, which is produced by cells of the thymus and helps control how important genes are switched on and off, was increased. This instructed the stem cell-like cells to rebuild the organ in very old mice.

This resulted in the thymus being regenerated to have a similar structure to those found in a young mouse, with the organ's function restored and the mice producing more white blood cells called T cells, which play a central role in fighting infection.

The breakthrough could lead to new therapies for the treatment of people with damaged immune systems and genetic conditions that affect thymus development, such as DiGeorge syndrome. However, the team says more work will need to be done to ensure the process can be tightly controlled before the approach is tested on humans.

"One of the key goals in regenerative medicine is harnessing the bodys own repair mechanisms and manipulating these in a controlled way to treat disease," says Dr Rob Buckle, the Head of Regenerative Medicine at the MRC. "This interesting study suggests that organ regeneration in a mammal can be directed by manipulation of a single protein, which is likely to have broad implications for other areas of regenerative biology."

The team's study is published in the journal Development.

Source: University of Edinburgh

Read more:
World-first regeneration of a living organ

Posted in Regenerative Medicine | Comments Off on World-first regeneration of a living organ

Study by prominent Brigham scientists retracted due to compromised data

Posted: April 10, 2014 at 5:48 am

A Brigham and Womens Hospital stem cell study, which raised the possibility that the human heart could repair itself, has been retracted after an internal investigation showed the researchers used compromised data.

The retraction comes just a week after a Japanese scientist was accused of fabricating data in a major stem cell paper that was led by a different Brigham scientist.

The authors of the retracted paper claimed they had found evidence that heart muscle can regenerate at a higher rate than previously thought. The work was part of a broad effort to discover the bodys natural regenerative abilities and harness them to create therapies that could repair damaged or diseased hearts.

The paper, published in 2012 in the journal Circulation, was withdrawn Tuesday by the journals publisher, the American Heart Association. An ongoing institutional review by Harvard Medical School and Brigham and Womens Hospital has determined that the data are sufficiently compromised that a retraction is warranted, the journal said.

This retraction is highly significant. In my 30 years in cardiovascular science I cannot recall a paper of similar prominence being retracted from Circulation, Dr. Charles Murry, codirector of the Institute for Stem Cell and Regenerative Medicine at the University of Washington, wrote in an e-mail. This appears to settle the controversy about the rate of cell replacement in the human heart.

Dr. Rose Marie Robertson, chief science officer for the American Heart Association, said that the journal received the retraction request from Harvard Medical School, in a letter that described concerns about several figures in the paper. She declined to elaborate on what the specific problems were.

The journals retraction notice does not specify whether the data irregularities were accidental or intentional, or which researchers were at fault. The authors include several high-profile scientists, including Dr. Piero Anversa, a cardiologist whose research has often raised questions from other scientists, and Dr. Joseph Loscalzo, chief of medicine at the Brigham.

Robertson said that based on the information provided by Harvard, the Heart Association did not have concerns about the role Loscalzo played in the paper. Loscalzo is the editor of the journal Circulation and recused himself from the retraction process, she said.

The study was supported by funds from the National Institutes of Health. In 2013, Anversas lab received $6.9 million from the agency, according to an NIH website. The federal Office of Research Integrity, which reviews allegations of scientific misconduct on federally sponsored research, said because of privacy reasons, it could not confirm or deny an investigation.

The key authors of the paper did not respond to direct requests for comment, and a Brigham spokeswoman declined to make them available. The hospital released a statement saying, Any questions, concerns, or allegations regarding research conducted at BWH are confidentially evaluated per the hospitals policies and federal regulations.

See the original post:
Study by prominent Brigham scientists retracted due to compromised data

Posted in Cell Medicine | Comments Off on Study by prominent Brigham scientists retracted due to compromised data

Mahendra Rao Joins The New York Stem Cell Foundation Research Institute

Posted: April 10, 2014 at 5:48 am

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, NY (April 9, 2014) Dr. Mahendra Rao, who has directed the Center for Regenerative Medicine at the National Institutes of Health (NIH CRM) since 2010, will join The New York Stem Cell Foundation (NYSCF) Research Institute as its Vice President for Regenerative Medicine, a newly created position, Susan Solomon, NYSCF Chief Executive Officer, announced today.

Dr. Rao, who holds an MD degree and a PhD in developmental neurobiology, is one of the nations most prominent stem cell scientists. He has over twenty years of experience in all aspects of the stem cell field including government, academia, and business. Before joining the NIH, Dr. Rao spent six years as the vice president of Regenerative Medicine at Life Technologies, Inc. (now Thermo Fisher Scientific) after serving as the chief of Neurosciences at the National Institute on Aging and co-founding Q Therapeutics, a neural stem cell company based in Utah. Dr. Rao is tenured at the University of Utah School of Medicine in both Neurobiology and Anatomy and has over twenty submitted and ten issued patents.

Dr. Raos expertise in translational research, academia, and industry make him a valuable asset in our mission to take stem cell research from the laboratory to the clinic in order to find cures for the diseases that affect those we love, Solomon said. We are delighted to have him on board.

Solomon said that recruiting Dr. Rao is a major coup for NYSCF as it builds on its existing successes and carries out its strategic goals. Dr. Raos expertise and experience in setting up a company and in leading the translational effort at NIH will complement their expertise in automation and high-throughput induced pluripotent stem (iPS) cell generation.

I am enthused about NYSCFs efforts to generate high-quality stem cell lines and partner with the pharma and academic communities. I am excited to be joining them to advance their goals, said Dr. Rao.

In addition to his business career, Dr. Rao has served on scientific advisory boards, editorial boards and review panels and on committees including as the U.S. Food and Drug Administrations Cellular, Tissue, and Gene Therapies Advisory Committee chair and as the California Institute of Regenerative Medicine and International Society for Stem Cell Research liaison to the International Society for Cellular Therapy. Currently, he sits on the board of Cesca Therapeutics, Inc. and serves as the Chief Strategy Officer and Chairman of the Scientific Advisory Board at Q Therapeutics.

"Mahendra is a widely-recognized and accomplished leader in stem cell research. He will be a major asset for NYSCF as we continue to develop new therapeutics for patients," said Dr. Zach Hall, NYSCF Board Member and former Director of National Institute of Neurological Disorders and Stroke.

About The New York Stem Cell Foundation

Read more here:
Mahendra Rao Joins The New York Stem Cell Foundation Research Institute

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Mahendra Rao Joins The New York Stem Cell Foundation Research Institute

News 12: Stem Cell Therapy for Pain – Video

Posted: April 9, 2014 at 6:45 pm


News 12: Stem Cell Therapy for Pain

By: Latest Pain Relief Solutions

View original post here:
News 12: Stem Cell Therapy for Pain - Video

Posted in Stem Cell Therapy | Comments Off on News 12: Stem Cell Therapy for Pain – Video

Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

Posted: April 9, 2014 at 6:45 pm

A doctor offering stem cell therapy may face charges for the death of a cancer patient who allegedly underwent treatment similar to that administered to former president and incumbent Pampanga Rep. Gloria Macapagal-Arroyo.

This was after it was found out that she is not a licensed doctor in the Philippines.

A report on GMA News TV's "News To Go" on Wednesday said a complaint has been filed against Dr. Antonia Carandang-Park at the National Bureau of Investigation (NBI) by Bernard Tan, who claims that his daughter, Kate, died after going through the said alternative treatment.Cancer patient Kate Tan received stem cell therapy from Dr. Antonia Carandang-Park, Gloria Arroyo's doctor.

Park owns the Tagaytay-based Green & Young Health and Wellness Center where Arroyoburdened by persistent trouble with her cervical spinesought treatment in 2012.

In an interview with GMA News, Tan said his daughter, who had Hodgkin's lymphoma (a type of cancer of the blood), was given "the same treatment that [Park] did with Gloria," which included "juicing diet, vegetable diet... acupuncture coffee enema, at 'yun na nga, stem cell."

Stem cell therapy introduces new adult stem cells into damaged tissue in order to treat disease or injury.

"Ang sabi niya, 'Give me three months, magaling na 'yan,'" Tan told GMA News. He added that his family was easily convinced to take their daughter to Park's wellness center because "Presidente na ng Pilipinas ang pumunta doon."

"Siguro naman na-scrutinize na nila 'yan, na-background check na nila 'yan," he said. "Kumbaga, 'yung credibility no'n, nag-build up na."

Kate was fed nothing but bananas and vegetable juices for three months, and had eight rounds of "embryonic" stem cell treatment, he said.

However, the 23-year-old lost even more weight, prompting the family to seek the assistance of a different doctor. Kate had eight rounds of 'embryonic' stem cell treatment, her father Bernard Tan said.Seven months later, in July 2013, Kate passed away.

Visit link:
Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

Posted in Stem Cell Therapy | Comments Off on Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

NIH Stem-Cell Program Closes

Posted: April 9, 2014 at 1:48 pm

The director of the agency's Center for Regenerative Medicine resigned on March 28 after just one clinical-trial award had been made

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine. Credit: NIH

Stem-cell researchers at the National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programs director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centers website was taken down on 4 April. Although no official announcement had been made at the timeNaturewent to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the center say that they have been left in the dark. When contacted byNatureon 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centers external advisory board, said that he had not yet been told of Raos departure or the centers closure.

The CRM was established in 2010 to centralize the NIHs stem-cell program. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the center had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Anderson says that the CRM will not continue in its current form. The field is moving so fast that we need to rethink. To that end, the NIH plans to hold a workshop in May to gather stem-cell researchers together and decide what to do with the program and its remaining budget. To me thats just smart science, he says. If somethings not on track you dont keep spending money on it.

One option could be to allow CRM projects to be absorbed by the National Center for Advancing Translational Sciences, an NIH institute established in 2011 to translate basic research into therapies. But Anderson says that participants at the workshop will also discuss whether the NIH needs to replace the CRM with another dedicated stem-cell program.

Go here to read the rest:
NIH Stem-Cell Program Closes

Posted in Cell Therapy | Comments Off on NIH Stem-Cell Program Closes

Page 2,143«..1020..2,1422,1432,1442,145..2,1502,160..»